ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,827.04
-1.54%
Dow Jones
41,938.45
-1.63%
US Dollar vs MXN
20.7185
0.00%
Brent Oil
79.285
0.00%
Bitcoin
94,513.65
-0.20%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Royalty Pharma PLC (RPRX)

  7. Royalty Pharma PLC (RPRX) Noticias

RPRX

Royalty Pharma (RPRX)

Royalty Pharma PLC
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:RPRX
FechaHoraFuenteTítuloSímboloCompañía
10/01/202516:26Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RPRXRoyalty Pharma PLC
10/01/202516:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RPRXRoyalty Pharma PLC
10/01/202506:30GlobeNewswire Inc.Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:RPRXRoyalty Pharma PLC
10/01/202506:15GlobeNewswire Inc.Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase ProgramNASDAQ:RPRXRoyalty Pharma PLC
09/01/202515:15GlobeNewswire Inc.Royalty Pharma Announces Dividend IncreaseNASDAQ:RPRXRoyalty Pharma PLC
27/11/202415:15GlobeNewswire Inc.Royalty Pharma to Present at Upcoming Investor ConferencesNASDAQ:RPRXRoyalty Pharma PLC
14/11/202415:30GlobeNewswire Inc.Royalty Pharma Announces Inaugural Prize for Impact in HealthcareNASDAQ:RPRXRoyalty Pharma PLC
07/11/202406:10GlobeNewswire Inc.Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 MillionNASDAQ:RPRXRoyalty Pharma PLC
06/11/202408:24Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RPRXRoyalty Pharma PLC
06/11/202406:15GlobeNewswire Inc.Royalty Pharma Reports Third Quarter 2024 ResultsNASDAQ:RPRXRoyalty Pharma PLC
04/11/202415:15GlobeNewswire Inc.Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for NiktimvoNASDAQ:RPRXRoyalty Pharma PLC
04/11/202415:01PR Newswire (US)Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™NASDAQ:RPRXRoyalty Pharma PLC
16/10/202415:15GlobeNewswire Inc.Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024NASDAQ:RPRXRoyalty Pharma PLC
11/10/202407:15GlobeNewswire Inc.Royalty Pharma Declares Fourth Quarter 2024 DividendNASDAQ:RPRXRoyalty Pharma PLC
03/09/202416:14GlobeNewswire Inc.Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding AgreementNASDAQ:RPRXRoyalty Pharma PLC
03/09/202416:06GlobeNewswire Inc.Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding AgreementNASDAQ:RPRXRoyalty Pharma PLC
28/08/202415:15GlobeNewswire Inc.Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare ConferenceNASDAQ:RPRXRoyalty Pharma PLC
12/08/202418:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RPRXRoyalty Pharma PLC
08/08/202406:00GlobeNewswire Inc.Royalty Pharma Reports Second Quarter 2024 ResultsNASDAQ:RPRXRoyalty Pharma PLC
29/07/202415:30Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:RPRXRoyalty Pharma PLC
24/07/202407:30GlobeNewswire Inc.Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human CapitalNASDAQ:RPRXRoyalty Pharma PLC
19/07/202407:15GlobeNewswire Inc.Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024NASDAQ:RPRXRoyalty Pharma PLC
17/07/202415:15GlobeNewswire Inc.Royalty Pharma Declares Third Quarter 2024 DividendNASDAQ:RPRXRoyalty Pharma PLC
04/06/202416:12Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RPRXRoyalty Pharma PLC
04/06/202415:15GlobeNewswire Inc.Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:RPRXRoyalty Pharma PLC
03/06/202416:15GlobeNewswire Inc.Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured NotesNASDAQ:RPRXRoyalty Pharma PLC
03/06/202415:59Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:RPRXRoyalty Pharma PLC
03/06/202407:39Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:RPRXRoyalty Pharma PLC
28/05/202406:10GlobeNewswire Inc.Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 MillionNASDAQ:RPRXRoyalty Pharma PLC
22/05/202415:10GlobeNewswire Inc.Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D PipelineNASDAQ:RPRXRoyalty Pharma PLC
 Showing the most relevant articles for your search:NASDAQ:RPRX

Su Consulta Reciente

NYSE
KOE
Str PD 7.75 Aon Cap
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados